Highlights Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
9.23 ^USD	-2.64%		-11.25%	-34.95%

10/05	UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating	MT
09/05	Amicus Therapeutics' Q1 Net Loss Narrows, Net Product Sales Rise	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amicus Therapeutics' Q1 Net Loss Narrows, Net Product Sales Rise	09/05	MT
Amicus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	09/05	CI
Amicus Therapeutics Swings to Q4 Earnings, Revenue Rises	28/02	MT
Earnings Flash (FOLD) AMICUS THERAPEUTICS Posts Q4 EPS $0.01, vs. Street Est of $-0.04	28/02	MT
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	28/02	CI
Amicus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Amicus Therapeutics Sees Revenue Growth of 21% in 2023	08/01	MT
Amicus Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	08/01	CI
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	20/12	DJ
Amicus Therapeutics' Q3 Net Loss Narrows, Revenue Rises	08/11	MT
Amicus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11	CI
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease	28/23/28	CI
New Paradigm Therapeutics, Inc. acquired worldwide rights of SD-101 from Amicus Therapeutics, Inc..	22/23/22	CI
Amicus Therapeutics Says Late-Onset Pompe Disease Therapy Approved by UK Healthcare Products Regulator	15/23/15	MT
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom	15/23/15	CI
Amicus Therapeutics Q2 Loss Narrows as Revenue Increases; Cuts 2023 Operating Expenses Outlook	08/23/08	MT
Amicus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/23/08	CI
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2023	08/23/08	CI
Amicus Therapeutics Inc. Announces Approval and Launch of New Pompe Disease Therapy in the European Union	27/23/27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Highlights

Filters